EUVIMEDEUVIMED entdecken
Crossref

Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENT

Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

Digestive Diseases and Sciences · 2026

DOI: 10.1007/s10620-026-09752-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Emily C L Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Ca…. Hauptthemen laut MEDLINE: Ustekinumab, Psoriasis, Colitis, Ulcerative, Crohn Disease. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inflammatory bowel disease (IBD) and psoriasis (PsO) share common immunopathogenic pathways involving IL-12 and IL-23. Biologic therapies targeting these cytokines are effective for Crohn's diseasse (CD), ulcerative colitis (UC), and PsO. In patients with IBD with comorbid PsO or psoriatic arthritis (PsA), IL-12/23 or IL-23 inhibitors are preferred, however it remains unclear whether their treatment outcomes are improved compared to patients without comorbid PsO/PsA. METHODS: This post hoc analysis used patient-level data from the UNITI (CD), SEAVUE (CD), and LUCENT (UC) trials. Patients treated with ustekinumab or mirikizumab were grouped by the presence or absence of comorbid PsO and/or PsA. Clinical response, remission, and endoscopic improvement were evaluated at week 8 (CD) and week 12 (UC). Logistic regression models adjusted for covariates assessed associations between comorbid PsO/PsA and outcomes. RESULTS: Among 1130 ustekinumab-treated CD patients, no significant differences were observed in week 8 clinical response (57.3 vs. 59.1%, p = 0.835) or remission (46.1 vs. 49.7%, p = 0.534) in those with vs. without PsO/PsA. Similarly, among 1849 mirikizumab-treated patients, week 12 clinical response (74.5 vs. 80.4%, p = 0.882), remission (14.9 vs. 21.3%, p = 0.385), and endoscopic improvement (25.5 vs. 30.0%, p = 0.693) were not significantly different. Logistic regression analyses confirmed no significant associations between PsO status and treatment outcomes after adjusting for covariates. CONCLUSION: The presence of comorbid PsO or PsA does not significantly impact the efficacy of ustekinumab in CD or mirikizumab in UC. These findings support the use of these therapies across diverse patient populations, irrespective of comorbid PsO or PsA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabPsoriasisColitis, UlcerativeCrohn DiseaseDermatologic AgentsHumansFemaleMaleTreatment OutcomeAdultMiddle AgedComorbidityRemission InductionAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Crohn’s diseaseIL-12IL-23Inflammatory bowel diseaseMirikizumabPsoriasisUlcerative colitisUstekinumab

Substanzen

UstekinumabmirikizumabDermatologic AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
  • Division of Gastroenterology, Northwestern University, Chicago, IL, USA.
  • Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada.
  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria.
  • Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada. Neeraj.narula@medportal.ca.

Zitieren

APA

Wong, E. C. L., Dulai, P. S., Marshall, J. K., Jairath, V., Reinisch, W., & Narula, N. (2026). Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENT. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-09752-6

Vancouver

Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENT. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-09752-6

BibTeX
@article{Wong2026,
  author = {Wong, Emily C L and Dulai, Parambir S and Marshall, John K and Jairath, Vipul and Reinisch, Walter and Narula, Neeraj},
  title = {Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENT},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  doi = {10.1007/s10620-026-09752-6}
}
Kostenlos starten →